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Abstract
Latently infected cells form the major obstacle to HIV eradication. Studies of HIV latency have been generally hindered by
the lack of a robust and rapidly deployable cell model that involves primary human CD4 T lymphocytes. Latently infected
cell lines have proven useful, but it is unclear how closely these proliferating cells recapitulate the conditions of viral latency
in non-dividing CD4 T lymphocytes in vivo. Current primary lymphocyte models more closely reflect the in vivo state of HIV
latency, but they are limited by protracted culture periods and often low cell yields. Additionally, these models are always
established in a single latently infected cell type that may not reflect the heterogeneous nature of the latent reservoir. Here
we describe a rapid, sensitive, and quantitative primary cell model of HIV-1 latency with replication competent proviruses
and multiple reporters to enhance the flexibility of the system. In this model, post-integration HIV-1 latency can be
established in all populations of CD4 T cells, and reactivation of latent provirus assessed within 7 days. The kinetics and
magnitude of reactivation were evaluated after stimulation with various cytokines, small molecules, and T-cell receptor
agonists. Reactivation of latent HIV proviruses was readily detected in the presence of strong activators of NF-kB. Latently
infected transitional memory CD4 T cells proved more responsive to these T-cell activators than latently infected central
memory cells. These findings reveal potentially important biological differences within the latently infected pool of memory
CD4 T cells and describe a flexible primary CD4 T-cell system to evaluate novel antagonists of HIV latency.
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Introduction
Within days after initial infection, HIV-1 establishes a persistent
latent reservoir in resting CD4 T cells and possibly other cell types
in all infected subjects [1,2,3]. Latently infected cells harbor
integrated HIV-1 proviral DNA but are otherwise indistinguish-
able from uninfected cells. Although they are rare in vivo, their
longevity and resistance to antiretroviral therapy make them a
major barrier to HIV-1 eradication [4,5,6].
Even studying latently infected cells from HIV-infected subjects
is challenging. These cells are very rare in the blood, and there are
no methods to enrich them. One approach for attacking the latent
reservoir is to use activating compounds that specifically induce
transcription of the latent provirus and translation of HIV proteins
but that are not toxic to uninfected CD4 T cells. To identify such
activators and to better understand the biological underpinnings of
HIV latency, a robust, flexible, and easy to construct model of
HIV latency in primary CD4 T cells is urgently needed.
To date, the best-characterized models of HIV latency involve
immortalized T-cell lines [7]. These systems have improved our
understanding of the relationship between T-cell stimulation and
proviral reactivation and the dynamic changes in chromatin
structure and transcription factor binding that accompany HIV
LTR reactivation [8,9,10,11,12]. However, these they are
imperfect surrogates: they do not recapitulate the non-dividing
G0 state of resting CD4 T cells in vivo [1,4]. Primary resting CD4 T
cells provide the optimal intracellular milieu for establishing
latency but are inefficiently infected in vitro, since HIV is impaired
during reverse transcription [13] and integration [10,14]. Most
primary cell models use one or more rounds of cellular stimulation
to remove these blocks, followed by HIV infection during the
return to a resting state [15,16,17,18,19]. Unfortunately, although
latently infected non-dividing T cells are generated, the process
often takes several weeks or months of continuous culture. Many
primary cell models also require cell sorting techniques to achieve
pure populations of cells before or after infection, a process that
greatly reduces the total yield of cells [20,21]. These features make
it difficult to execute large-scale screening for agents that could
reactivate and eliminate latent proviruses.
Recent reports suggest latent reservoir in vivo might be more
complex than thought. In one study of patients on antiretroviral
therapy with clinically undetectable viral levels, two cellular
reservoirs were detected. One decayed with antiretroviral therapy,
and one did not [22]. In a second study, proviral DNA was
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subpopulations, specifically central memory and transitional
memory cells [23]. Although central memory T cells typically
harbor a larger proportion of the latent proviruses, the transitional
memory cells appear to live longer and are continually renewed by
cytokine-induced homeostatic proliferation [23]. It is unknown
approaches aimed at purging latent proviruses will be as effective
in these different memory cell populations. In addition, since
current models of HIV-1 latency involve one or more rounds of
cellular stimulation, it is difficult to know if latency is reproducibly
established in both memory cell types as it is in vivo. A model of
HIV-1 latency that allows to examine latency in both memory
CD4 T-cell subpopulations would be very useful.
In the model of HIV-1 latency originally described by the
O’Doherty laboratory, resting CD4 T cells are directly infected by
spinoculation [20,24]. With its high levels of virion attachment, a
proportion of viruses likely complete reverse transcription and
integration [24]. Post-integration latency is established in these
spinoculated cells within 72 h in all CD4 T-cell subsets, including
both naive and memory T cells [25,26,27]. Latent proviruses are
activated after an additional 72 h of cellular stimulation [24],
indicating that latency can be established and reactivation assessed
within 6 days. The speed and reproducibility of this system made it
an ideal starting point for developing an even more dynamic
primary CD4 T-cell model of HIV latency suitable for screening of
reactivating agents.
Using novel reporter viruses, we describe an improved version
of this primary CD4 T-cell model that can be used to study latency
in all subsets of CD4 T cells. We specifically evaluated differences
in HIV latency in central and transitional memory CD4 T cells.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All individuals provided written
informed consent for the collection of samples and subsequent
analysis as approved by the Institutional Review Board of Stanford
University Blood Bank.
Construction of NL4-3 luciferase and NL4-3
mCherry:Luc. In addition to the green fluorescent protein
(GFP) reporter virus that measures the number of cells in which
the latent HIV provirus is successfully reactivated, we created a
luciferase-expressing virus that measures overall levels of
transcriptional reactivation of latent HIV. A fully infectious
molecular clone of NL4-3 expressing firefly luciferase from the
native LTR was prepared, essentially as described below,for the
replication-defective pseudotyping vector pNL-Luc-E
2R
2.B o t h
pNL-Luc-E
2R
2 and the fully infectious molecular clone, pNL4-3,
were obtained from the AIDS Research and Reference Reagent
Program. pNL-Luc-E
2R
2 was originally generated by transposition
of the firefly luciferase gene from the molecular clone pHXB-Luc
[28] into pNL4-3 between the BamHI (nt 8021) and XhoI sites (nt
8443) within the nef coding region [29]. The BamHI-XhoI fragment
of pNL-Luc-E
2R
2 was shuttled into pNL4-3 to yield an env+/vpr+
vector that, when transfected, produces viruses capable of multiple
rounds of infection and luciferase driven from the viral LTR. We
also prepared an HIV dual reporter vector expressing mCherry and
luciferase to simultaneously measure the number of cells containing
reactivated latent provirus and the overall strength of the viral
transcriptional response in these cells. To generate a fully infectious
molecular clone expressing both of these reporters, firefly luciferase
was inserted in place of the puromycin resistance gene in a modified
pSicoR lentiviral expression vector termed pSicoRMS2 (a kind gift
of Matt Spindler and Bruce Conklin, Gladstone Institute of
Cardiovascular Disease). This vector contains an EF-1 alpha–
driven mCherry:Puromycin cassette in which mCherry and
puromycin are separated by a picornavirus-derived ribosomal
skipping T2A sequence. The T2A sequence (ccccgggagggcagaggaa-
gtcttctaacatgcggtgacgtggaggagaatcccggccctcga) allows balanced
production of the two flanking gene products [30,31]. The firefly
luciferase gene was subcloned in place of puromycin with XmaI and
EcoRI. Clones were then tested for mCherry and luciferase
expression after transfection of 293T cells. Mcherry:T2A:luciferase
was amplified using PCR primers containing 59 and 39 sequences
from the pNLENG1 vector (NL4-3 GFP). This amplicon was
digested with BamHI and SalI and inserted into the pNLENG1
vector backbone at the unique BamHI and XhoI sites. The XhoI
site was destroyed in the cloning process, resulting in an S34C
mutation in Nef.
Isolation of CD4 T cells. Peripheral blood mononuclear cells
(PBMC) were isolated by Ficoll-Hypaque density gradient
centrifugation of buffy coats from HIV-seronegative donors
(Stanford University Medical Center Blood Bank). PBMCs were
immediately processed to isolate CD4 T cells or maintained in
RPMI 1640 medium supplemented with 10% FBS and penicillin/
streptomycin for up to 24 h before cellular isolation. Longer periods
of culture before cellular isolation were avoided to eliminate higher
levels of nonspecific cellular activation. Total CD4 T cells were
isolated by negative selection, according to manufacturer’s protocol,
with the EasySep CD4+ T-cell Enrichment Kit (Stem Cell
Technologies). Memory CD4 T cells were isolated using EasySep
Memory CD4+ T-cell Enrichment Kit, according to manufacturers
protocol (Stem Cell Technologies). Resting memory CD4 T cells
were isolated by EasySep custom cell purification kit that depleted
cells expressing CD8, CD14, CD16, CD19, CD20, CD41, CD56,
GlyA, CD123, CD25, HLA-DR, and CD69. Isolated CD4 T cells
were cultured in RPMI as described above at a concentration of
1610
6 cells/ml for 2–48 h before HIV infection.
Spinoculation of CD4 T cells. CD4 T cells were counted,
collected as pellets by centrifugation at 2006g for 10 min at room
temperature, and resuspended in the appropriate volume of
concentrated viral supernatant. Typically, 50–200 ng of p24
Gag
per 4610
5 CD4 T cells were used. Spinoculations were performed
in 96-well V-bottom plates with up to 5610
5 CD4 T cells per well;
15-ml Falcon conical tubes were used for larger quantities of cells
(up to 1610
7 CD4 T cells/tube). All spinoculations were
performed in volumes of 200 ml or less. Cells and virus were
centrifuged at 12006 g for 1.5–2 h at room temperature. After
spinoculation, cells were pooled and cultured at a concentration of
1610
6 cells/ml in RPMI 1640 containing 10% FCS and
supplemented with 5 mM saquinavir for 3 days to prevent
residual spreading infection. Saquinavir was obtained through
the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH.
Flow cytometry
To determine the presence of memory cell subpopulations or for
cell sorting of memory cell populations, cells were stained with
CD45RA-APC-Cy7 (1:40), CCR7-PE-Cy7 (1:40), CD27-APC
(1:5), and either CD45RO-FITC (1:20) for cells infected or to be
infected with NL4-3 mCherry:Luc or CD45RO-PE for cells
infected or to be infected with NL4-3 GFP. Cells were stained for
30 min at 4uC, washed two times with PBS containing 2% serum,
and fixed in 2% paraformaldehyde for flow cytometric analysis or
left unfixed for cell sorting. Cells were analyzed with a Becton
Dickinson (BD) LSRII instrument or sorted with a BD FACS Aria
II flow cytometer.
Primary Cell Model of HIV-1 Latency
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Cells were counted and collected as pellets by centrifugation at
2006 g for 10 min. Cells were then plated in 96-well U-bottom
plates at concentrations of 2.5610
5–1610
6/200 ml in the presence
of 30 mM raltegravir and the indicated activator. Raltegravir
(donated by Merck & Co.) was obtained from the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH
(Cat # 11680). Unless otherwise indicated, cells were cultured
either in medium alone or stimulated with 200 nM PMA (Sigma),
1.5 mM ionomycin (Sigma), 10 mg/ml phytohemagglutinin (PHA)
(Sigma), 10 ng/ml TNF-a, anti-CD3+anti-CD28 beads at a ratio
of 1:1 (Invitrogen), 62.5 ng/ml IL-7 (R&D Systems), or 12.5 ng/
ml interleukin (IL)-15 (R&D Systems). TSA (Sigma), prostratin
(Sigma), hexamethylene bisacetamide (HMBA) (Sigma), VPA
(Sigma), and SAHA (NCI Chemical Carcinogen Repository,
Midwest Research Institute) were tested at the indicated
concentrations. Cells were harvested at the indicated times after
spinoculation, washed one time with PBS, and lysed in 65 mlo f
Glo Lysis Buffer (Promega) or fixed in 2% paraformaldehyde for
GFP or mCherry analysis. For luciferase samples, after 15 min of
lysis, the luciferase activity in cell extracts was quantified with a
BD Monolight Luminometer after mixing 50 ml of lysate with
50 ml of substrate (Luciferase Assay System-Promega). Relative
light units were normalized to protein content determined by BCA
assay (Pierce).
Integration Assay
HIV integration analysis was performed as described [32]. HIV
integration events were normalized to RNaseP (Applied Biosys-
tems) to determine HIV integration events/cell.
Results
Rapid generation of latently infected CD4 T-cells ex vivo
To establish latently infected primary CD4 T cells, we used
spinoculation to efficiently deliver large quantities of virions to
resting CD4 T cells [24]. The original model of HIV-1 latency
developed in the O’Doherty laboratory, like many others, involved
fluorescence-activated cell sorting (FACS) to isolate highly purified
resting CD4 T cells [24]. To simplify the cell-purification process,
increase cell yield, and leave the desired cell population
‘‘untouched,’’ we used a single-step negative-selection strategy.
Specifically, cells were incubated with antibody-bound magnetic
beads to isolate total CD4 T cells (CD3+CD4+) or memory
(CD4+CD45RO+) CD4 T cells from the peripheral blood of
uninfected human volunteers. Typically, the CD4 T-cell yield was
25–30% (total CD4) or 10–15% (memory CD4) of the total PBMC
with purities of 97–99% (Figure 1A, Figure S1A).
This assay required a marker to monitor the number of cells in
which latent proviruses were reactivated. A full-length, replication-
competent HIV expressing EGFP in the Nef position with Nef
expressed under the control of an IRES element (NL4-3 GFP)
(Figure 1B) [33,34] provided useful information about the number
of reactivated cells but little quantitative data on the absolute levels
of reporter protein production within these cells. We generated a
replication-competent version of NL4-3 NL4-3 Luciferase and a
third reporter expressing mCherry and firefly luciferase separated
by a T2A ribosomal skip sequence [30,31] (Figure 1B). In the
latter reporter virus, mCherry and luciferase are expressed from
the same LTR-driven mRNA and translated as separate proteins
in equivalent quantities, and Nef is expressed under the control of
an IRES element. This latter virus permitted simultaneous
assessment of the number of cells in which latent virus was
reactivated (mCherry) and the strength of viral reactivation in the
cells (luciferase). Stimulation with PMA and ionomycin produced
2–3.9-fold more GFP-expressing cells than uninduced cells, a 6.6–
7.3-fold increase in mCherry-positive cells, and a 61–248-fold
increase in luciferase activity, depending on the use of single or
dual reporter viruses and the time selected for analysis
(Figure 1C,D).
Reactivation of latent proviruses was easily detectable after only
24 h of stimulation with PMA and ionomycin. Higher levels were
detected at 48 h (Figure 1C,D). Consistent results were obtained
when more highly purified memory CD4 T cells or resting
memory CD4 T cells were used, indicating that more extensive
purification steps are not necessary to obtain physiologically
relevant data (Figure S1B,C). Finally, this reactivation assay
proved highly reproducible, based on the analysis of 10
independent donors who exhibited similar profiles with variation
observed only at the level of proviral reactivation and background
under unstimulated conditions (Figure S2).
Latently infected CD4 T cells harbor integrated HIV-1
DNA
Unintegrated HIV-1 DNA is unstable and does not represent a
major mechanism for long-term persistence of HIV in vivo [13,35]
Conversely, stably integrated HIV proviruses can be highly
persistent and are responsible for durable forms of latent HIV
infection. As such, relevant models of HIV-1 latency must
specifically detect reactivation of integrated proviruses and exclude
background viral protein production from unintegrated forms. To
determine if the detected GFP, luciferase, and mCherry:luciferase
signals were derived from integrated proviruses, we examined
reactivation levels in the absence or presence of raltegravir, a
potent HIV integrase inhibitor [36]. Optimal concentrations of
raltegravir were first determined using spinoculation conditions to
infect permissive, activated CD4 T cells (Figure S3). Cultures were
treated with raltegravir immediately after spinoculation (Figure 1A,
pre-treatment). Under these conditions, the luciferase signal after
reactivation was almost abolished, validating the potent antiviral
activity of raltegravir at the concentration tested. A few GFP
+ cells
were detected after raltegravir pre-treatment, possibly reflecting
low-level expression from multiply spliced mRNAs produced by
unintegrated viruses [37] (Figure 2A). Next, to determine if the
reporter signals emanated from integrated latent proviruses,
raltegravir was added immediately before reactivation rather than
after spinoculation (Figure 1A, Pre-activation). Under these
conditions, levels of reactivation were 20–45% lower than in
untreated samples (Figure 2A). These findings suggest that 20–
45% of the signal generated during reactivation is from viruses
that had not yet completed integration at the time of stimulation.
Activation-induced integration and expression of these viruses
were inhibited by raltegravir. Conversely, 55–80% of the signal
appears to derive from integrated proviruses that are insensitive to
raltegravir when added at reactivation. To eliminate the signal
contributed by preintegration forms of latent HIV and to inhibit
HIV spread in the cultures, raltegravir was routinely added before
reactivation in all subsequent experiments.
The insensitivity of the reporter signal to raltegravir at
activation strongly argued for the presence of integrated latent
proviruses in these cells. To confirm the presence of integrated
proviruses, we performed Alu-gag PCR to specifically detect
integrated HIV DNA [32] (Figure 2B). An Alu-gag PCR signal
was not detected when cells were infected in the presence of
raltegravir, AMD3100 or Efavirenz, validating the specificity of
the assay for integrated HIV DNA (Figure 2B, left panel). A gag
PCR to detect both integrated and unintegrated forms of HIV
DNA demonstrated that infection was blocked at the level of
Primary Cell Model of HIV-1 Latency
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30176Figure 1. Establishing postintegration HIV-1 latency in primary CD4 T cells and reactivating virus. (A) Production of a primary cell model
of HIV-1 latency. Total CD4 T cells were isolated from PBMC with a single-step negative-selection procedure with magnetic beads to remove
unwanted cell subpopulations. Within 24 h, isolated cells were spinoculated at 12006 g for 2 h at room temperature with viral supernatants
corresponding to NL4-3 GFP IRES Nef, NL4-3 Luciferase, or NL4-3 mCherry:Luciferase viruses as schematically depicted in (B). After spinoculation, cells
were placed in medium containing 5 mM saquinavir and cultured for 3 days. Cells are then counted and plated in 96-well plates in medium containing
30 mM raltegravir and various stimulators. (C) Reactivation profiles of cells latently infected with NL4-3 GFP IRES Nef, NL4-3 Luciferase, or NL4-3
mCherry:Luciferase. Latently infected cells were cultured with medium alone or medium containing 200 nM PMA and 1.5 mM ionomycin and
harvested after 24 or 48 hours of culture. GFP- or mCherry-expressing cells were quantified by flow cytometry, and the percentage of GFP
+ or
mCherry cells was calculated based on uninfected controls. Luciferase levels are reported as relative light units (RLU) and have been normalized to
total protein content in cell lysates to control for different cell proliferation rates. All samples were analyzed in triplicate with error bars representing
Primary Cell Model of HIV-1 Latency
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Of note, the amount of integrated HIV DNA varied from donor to
donor with a range of 0.65–7.8 copies of integrated HIV DNA per
100 cells (Figure 2C). Levels of GFP expression occurring after
reactivation correlated with the frequency of cells harboring
integrated provirus (Figure 2C). Interestingly, levels of GFP
expression were consistently slightly lower than integration levels,
suggesting some cells remain latent after stimulation or cells that
respond to stimulation harbor more than one copy of HIV DNA.
Latently infected cells exhibit robust responses to T-cell
activators
Various cellular activating agents stimulate latent HIV provi-
ruses in primary cell models and primary cells from HIV-1-
infected individuals [18,38,39]. First, uninfected resting CD4 T
cells were treated with various concentrations of known cellular
activating agents and analyzed for CD25 expression, CD69
expression, and viability to determine optimal activation concen-
trations (Figure S4 and data not shown). We then screened a panel
of activating agents at optimal concentrations for relative efficacy
in our model. The most effective agents were, in decreasing order,
anti-CD3+anti-CD28 antibodies, PHA+IL-2 and PMA+ionomy-
cin. These findings mirror the most effective agents for reactivating
latent virus from patient samples [4,39,40] (Figure 3A). The results
with replication-competent NL4-3 Luciferase, NL4.3 mCherry:-
Luc, and GFP-expressing viruses correlated well, although the
dynamic range of the response was again greatest with the
luciferase reporters (Figure 3 and Figure S5). Of note, TNF-a,a
potent activator of HIV-1 latency in many cell line models, was
ineffective in this primary cell model. This result mirrors the poor
effectiveness of TNF-a when added as a single agent activator in
primary patient samples and is consistent with the minimal
expression of TNFR1 or TNFR2 on resting CD4 T cells
[18,39,41,42]. These findings provide further support for the
+/2 SD. Results are representative of those obtained in analyses of at least 10 independent donors with each virus. (D) Flow cytometric gating and
analysis of cells latently infected with NL4-3 GFP IRES Nef or NL4-3 mCherry:Luciferase 24 or 48 hours after stimulation with PMA and ionomycin.
Forward scatter versus side scatter plots show cells infected with virus and left unstimulated or stimulated for 24 h.
doi:10.1371/journal.pone.0030176.g001
Figure 2. Latently infected cells harbor integrated proviruses. (A) Cells were cultured in the presence (pre-treatment) or absence (no pre-
treatment) of 30 mM raltegravir that was added immediately after spinoculation. After 3 days, cells were washed and stimulated with PMA+ionomycin
in the presence or absence of 30 mM raltegravir (pre-activation). Results are representative of data obtained using three independent donors with
each reporter virus. Error bars represent +/2SD of triplicate experiments. (B) CD4 T cells were isolated and pre-treated with 30 mM raltegravir, 250 nM
AMD3100, 100 nM Efavirenz, or medium alone for 30 min before spinoculation. Cells were spinoculated and then cultured in the presence or absence
of each antiretroviral drug. Three days after spinoculation, total DNA was isolated from the cells, and levels of HIV integration were determined by
Alu-gag qPCR (left panel) or levels of total HIV DNA were determined by gag qPCR (right panel). Viral integration levels were compared in cultures
incubated in medium alone versus in the presence of raltegravir (RTGR), AMD3100 (AMD), or Efavirenz (EFV) antiviral drugs to confirm the specificity
of the assay. Data shown represent an average of six replicate PCR samples +/2 SD. Data are presented as the number of copies of HIV DNA per 100
cells. (C) Three days after spinoculation, cells were either lysed for DNA isolation or stimulated with PMA+ionomycin for 24–72 hours. Peak GFP
expression data are shown as the mean of three replicate samples. HIV integration was analyzed by Alu-gag qPCR to specifically detect integrated
proviral DNA, and levels were normalized to levels obtained for the single copy RNaseP gene. Data shown are average of six replicate PCR samples +/
2 SD. Data are presented as copies of integrated HIV DNA/100 cells and the number of GFP+ cells/100 cells.
doi:10.1371/journal.pone.0030176.g002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30176Figure 3. Kinetics of HIV-1 reactivation. (A) Latently infected cells were generated as described in Figure 1 with NL4-3 Luciferase virus or NL4-3
mCherry:Luc virus. Cells were either cultured in the presence of media alone or stimulated with 200 nM PMA, 200 nM PMA and 1.5 mM ionomycin,
10 mg/ml PHA, 10 mg/ml PHA with 100 units/ml IL-2, 10 ng/ml TNF-a, anti-CD3+anti-CD28 beads (ratio 1:1), 100 units/ml IL-2, 62.5 ng/ml IL-7, or
12.5 ng/ml IL-15. Cells were harvested after 48 h of stimulation. RLU shown were normalized based on total protein present in the various cell lysates.
All stimulations were performed in triplicate with error bars representing +/2 SD. Results are representative of experiments performed with cells from
four independent donors. (B) Latently infected cells from the same individual donor were stimulated with anti-CD3+anti-CD28 beads (ratio 1:1),
200 nM PMA with 1.5 mM ionomycin, or 10 mg/ml PHA with 100 units/ml IL-2 and harvested at the indicated times post-stimulation. Results are
representative of kinetic experiments performed with cells isolated from three independent donors.
doi:10.1371/journal.pone.0030176.g003
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1 latency (Figure 3A).
HIV reactivation can be rapidly detected after T-cell
stimulation
Kinetic studies of HIV-1 reactivation in primary cells are often
hindered by low signals and small sample sizes. To assess the
kinetics of proviral reactivation in our model, we selected the three
classes of strongest activators: anti-CD3+anti-CD28, PHA+IL-2,
and PMA+ionomycin. The stimulators exhibited different kinetics
within the first 12 h after reactivation. With the large dynamic
range for the NL4-3 luciferase virus, we consistently detected viral
reactivation within only 2–6 h (Figure 3B). For PMA+ionomycin
with its rapid mechanism of cellular activation, we saw reactivation
in cells within 2 h (Figure 3B, see insets). PMA+ionomycin and
PHA+IL-2 induced a continuous increase in viral reactivation over
72 h, and anti-CD3+anti-CD28-induced reactivation typically
peaked after 54 h. These kinetic results again highlight the robust
nature of this T-cell model of HIV-1 latency. The rapid
reactivation kinetics with PMA+ionomycin suggests that HIV
latency can be rapidly reversed with the appropriate inducing
agents and that the process may not require new protein synthesis.
Strong cellular activators potently reactivate latent
proviruses
Next, we tested combinations of cellular activating agents for
their abilities to activate latent HIV proviruses in the primary CD4
T cells. Specifically, we interrogated agents that induce NF-kBo r
P-TEFb or that act by promoting changes in chromatin structure
surrounding the HIV-1 LTR [11,18,43]. Three different histone
deacetylase (HDAC) inhibitors (i.e., SAHA, VPA, and TSA) were
tested over a 4-log concentration range (Figure 4A). Prostratin was
used as a strong activator of NF-kB, and HMBA was tested as a
strong activator of P-TEFb. Prostratin added as a single agent
matched the potent inducing activity of the combination of
PMA+ionomycin. (Figure 4A). One clear drawback with prostratin
was its rather narrow dose range (1–10 mM) (Figure 4A,B). SAHA
displayed reduced activity at concentrations greater than 10 mM,
due mainly to its cellular toxicity (Figure 4A and data not shown).
HMBA and VPA exhibited weaker inducing activity in these
primary CD4 T cells with effects occurring only in the mM range.
These findings further highlight how this primary cell model
system can be used as an experimental platform to screen
candidate activators and for subsequent dose-ranging studies.
Transcriptional activators fail to synergize with
chromatin-modifying agents
Increasing interest has focused on combinations of inducers to
synergistically activate latent proviruses. Multiple mechanisms
have been proposed for HIV-1 latency, and simultaneous
induction of diverse pathways might be more effective than
relying on a single pathway (reviewed in [6]). For example, in cell
line models of HIV-1 latency, prostratin and HDAC inhibitors
synergistically reactivated latent proviruses [44,45]. Additionally,
reactivation studies in CD8-depleted PBMCs from HAART-
treated subjects suggested HDAC inhibitors and transcriptional
activators might work together in these cells as well [46].
Using our primary CD4 T-cell model system, we tested
combinations of drugs, each at its most effective concentration.
Prostratin is a potent stimulator of NF-kB in CD4 T cells. At 1–
10 mM, it reactivated HIV-1 latency as effectively as T-cell
receptor agonists in every donor evaluated. To determine if
additional latent provirus could be reactivated, we evaluated
prostratin in combination with HDAC inhibitors. The drug
pairings were designed to promote increased latent proviral
reactivation by triggering complementary intracellular signaling
pathways. Combinations of drugs typically worked somewhat
better than single drugs (Figure 4B). Results were consistent when
the NL4-3 GFP IRES Nef virus was employed indicating that
combinations of drugs also did not achieve a significantly higher
proportion of reactivated cells (Figure S6). Modest synergies were
seen with some combinations (e.g., 10 mM prostratin+10 mM
SAHA), but they were typically transient and disappeared after
48 h (Figure 4B). However, unlike prostratin alone, the effects of
the synergies were not consistent among different donors
(Figure 4B and Table 1). Prostratin at 1 mM or more was typically
as effective as PMA+ionomycin. This finding is consistent with
results from other primary T-cell models of latency, suggesting that
addition of a strong activator of NF-kB is sufficient for robust
HIV-1 reactivation [18,40,43] but in contrast to one latency model
formed in central memory CD4 T cells where NF-kB inducers
were ineffective [15]. Although HDAC inhibitors showed modest
viral reactivation in all donors tested, these effects were
overshadowed with a strong transcriptional activator.
Next, each HDAC inhibitor was screened in combination with
HMBA, which upregulates HIV-1 transcription primarily by
activating the P-TEFb complex of cyclin T1 and CDK9 [47].
Again, only modest, transient synergy was observed with any of
the combinations (Table 1). Thus, the robust synergistic effects of
HDAC inhibitors in combination with prostratin and other
agonists in J-Lat cells are not readily translated to these primary
CD4 T cells. However, these studies do highlight the utility of this
primary cell model of HIV latency for rapid screening of
compounds for synergistic activating effects.
Transitional memory CD4 T cells are preferentially
reactivated by NF-kB inducers
Recent studies revealed cellular heterogeneity within the latent
reservoir [22,23]. Specifically, central memory and transitional
memory CD4 T cells with latent viruses and likely turnover at
different rates [23]. Since our model involves minimal manipu-
lation of the circulating memory CD4 T-cells, we determined if
latency was established in both of these cell types and if latent
proviruses in each displayed distinguishing patterns of reactivation.
Memory CD4 T cells (CD4+CD45RO+) were isolated from
PBMC, and post-integration latency was established as described.
Cells were activated with a subset of inducers that reproducibly
gave the highest signals after reactivation, including PMA+iono-
mycin, anti-CD3+anti-CD28 antibodies, and prostratin. We also
tested IL-7, because of its role in homeostatic proliferation of these
cells and its ability to reactivate latent HIV [18,23,24]. Total
memory cells, central memory (CCR7+CD27+), or transitional
memory (CCR7-CD27+) were monitored by flow cytometry, and
the percentage of cells within each subset expressing either GFP or
mCherry after adding inducers was determined (Figure 5A). The
results are presented as fold change in fluorescence between
induced and uninduced cells, thereby controlling for differences in
background fluorescence in the different cellular subsets. While
proviral latency was established in both populations, transitional
memory cells (TTM) were significantly more susceptible to
reactivation with PMA+ ionomycin, anti-CD3+anti-CD28 anti-
bodies, and prostratin as assessed with GFP and mCherry reporter
viruses (Figure 5A). Central memory cells (TCM) and transitional
memory cells (TTM) exhibited similar levels of reactivation with IL-
7. These findings suggest that these different subsets of latently
infected memory CD4 T cells respond differently to strong
activators of nuclear NF-kB expression but similarly to IL-7.
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may be more susceptible to certain inducers, adding these inducers
might have changed the distribution of central and transitional
memory cells even in a short experimental time. To address this
possibility, we sorted memory cells into transitional and central
memory cell subsets (Figure 5). Cells were infected with NL4-3
mCherry:Luc, and HIV latency was established in each. Cells
were reactivated (Figure 5A), although the very low numbers of
recovered cells did not permit analysis of all inducers with cells
from a single donor (Figure 5C). Since these populations are no
longer cultured in bulk, we chose to analyze the fold change in
luciferase levels after stimulation since this reporter consistently
yielded the greatest dynamic range. As in the prior experiments,
transitional memory cells were more susceptible to stimulation
with PMA+ionomycin, anti-CD3+anti-CD28 antibodies, and
prostratin but not IL-7. Importantly, although these cell types
exhibited relative differences in the level of reactivation achieved
with each inducer, both cell types were reactivated with each
inducer.
Discussion
We report here a novel primary T-cell model of HIV-1 latency.
Our model has several advantages over existing models [7,20,21].
Its speed and reproducibility facilitate the screening of unknown
compounds and unique combinations and concentrations of
known activators. The novel mCherry-luciferase dual reporter
virus allow us to assess the number of cells responding to a specific
inducer (mCherry) and the magnitude of the response within the
entire population (luciferase). The single-step negative purification
step for CD4 T cells from peripheral blood minimizes the
manipulations of cells. We estimate that 200–1000 reactivation
conditions can be screened with cells from a single unit of blood.
The high signal-to-noise ratio with the luciferase reporter viruses
suggests that non-optimized inducers with low reactivation activity
can be readily detected. Thus, this assay could be valuable in the
search for novel inducers or combinations of inducers.
Cells respond in many ways when HIV-1 proteins are expressed
at high levels, causing differences in internal and external signaling
properties. Our kinetic studies revealed viral proteins can be
detected in latently infected cells within 2 h after induction. The
full-length, replication-competent virus in this system also closely
mimics latent HIV-1 infection in vivo and could be useful for
monitoring potential changes in cellular responses associated with
reactivating latent proviruses and expressing viral proteins. Of
note, Nef+ and Nef2 viruses responded to activators with similar
kinetics, suggesting that Nef may not be important after viral
reactivation. Effectiveness of ‘‘purging’’ of the latent reservoir can
also be monitored in this system since cells are infected with a
cytopathic and replication-competent virus. Finally, the release
and accumulation of viral particles after reactivation can be
quantified, thus providing useful information on the efficacy of
various stimuli.
Using this model, post-integration HIV latency can be rapidly
and reproducibly established. Our findings indicate that HIV
integration levels correlate well with the levels of HIV expression
observed after cellular stimulation [24]. However, even with the
most potent inducers, HIV reactivation levels reflect only a
fraction of the total integrated HIV DNA detected. This finding
suggests a variegated response within the entire population of
latently infected cells with each cell likely containing a single
integrated provirus. However, we cannot completely exclude the
possibility that some cells contain more than one provirus,
although the frequency of such an event is likely to be very low.
Overall, we believe these results are comparable to results in
patient samples where approximately 99% of the proviral DNA
cannot be detected by limiting dilution co-culture growth assays
[1] or where only a fraction of J-Lat CD4 T cells each containing a
Figure 4. Multiplex screening of inducing compounds on the reactivation of HIV-1 latency. (A) Latently infected cells were stimulated
with 10-fold increasing concentrations of SAHA, TSA, HMBA, VPA, or prostratin. Cells were treated with 200 nM PMA+1.5 mM ionomycin as a positive
control. The highest and lowest concentrations of the 10-fold dilution series are indicated for each compound tested. Stimulations were performed in
triplicate reactions and error bars represent +/2 SD. (B) Cells were treated for 24 or 48 h with the indicated concentration of compounds. Results are
representative of independent experiments performed with at least three independent donors.
doi:10.1371/journal.pone.0030176.g004
Table 1. Summary of synergistic activity of inducer
combinations.
24 Hours 48 Hours
Prostratin+TSA
Donor 672 1.2 ,1.0
Donor 216 ,1.0 1.4
Donor 890 1.2 ,1.0
Prostratin+SAHA
Donor 672 1.2 ,1.0
Donor 216 ,1.0 1.7
Donor 890 1.9 ,1.0
Prostratin+VPA
Donor 672 1.2 ,1.0
Donor 216 ,1.0 ,1.0
Donor 890 1.4 ,1.0
HMBA+TSA
Donor 672 1.1 ,1.0
Donor 216 1.3 ,1.0
Donor 044 ,1.0 1.3
HMBA+SAHA
Donor 672 ,1.0 ,1.0
Donor 216 ,1.0 2.1
Donor 044 1.3 1.2
HMBA+VPA
Donor 672 ,1.0 ,1.0
Donor 216 ,1.0 ,1.0
Donor 044 ,1.0 1.4
Values are the calculated synergistic index of the inducers when used in
combination versus when used as single agents [44]. Each value represents the
highest synergistic index value obtained for a given donor and time period of
simulation over a range of six dose combinations (prostratin) or four dose
combinations (HMBA). Combinations of the following dose concentrations were
used: prostratin (0.1, 1, 10 mM); HMBA (0.5, 5 mM); TSA (0.1, 1 mM); SAHA (1,
10 mM); VPA (0.1, 1 mM). The index of synergism was calculated with the
following formula: the luciferase value from cells after stimulation with the
indicated combination of inducers divided by the sum of the luciferase values
from cells after stimulation with each inducer separately. Background luciferase
values from unstimulated samples were subtracted prior to synergistic index
calculation. Combinations of given inducers that gave a synergistic index .1
are considered synergistic and shown in bolded text.
doi:10.1371/journal.pone.0030176.t001
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useful for further characterizing the subset of latently infected cells
that fail to respond to classic reactivation signals to discern the
underlying mechanism(s).
Numerous model systems and data generated with patient-
derived cells suggest that NF-kB is important in reactivating HIV-
1 from latency [18,38,39,40,43,48,49]. However, another highly
robust primary CD4 T-cell model of HIV-1 latency did not agree
[15]. Although our findings suggest that CD4 memory T-cell
subsets achieve different levels of activation with various inducers,
NF-kB appears to be involved. Interestingly, latently infected
transitional memory CD4 T cells preferentially responded to
prostratin, a strong inducer of NF-kB but not NFAT [48]. Model
systems that more closely resemble a central memory CD4 T-cell
phenotype might be less dependent on NF-kB for viral
reactivation [15]. Nevertheless, our findings indicate that all
inducers reactivate HIV in each of these memory subsets, although
the magnitude of reactivation appears greater in transitional
memory CD4 T cells. We believe this primary model system will
prove useful for continuing to dissect the curious differences
between the two memory cell populations.
The precise mechanism by which the latent reservoir is
established and maintained in vivo is an area of ongoing debate.
More studies are needed to determine the relative contributions of
different cellular latent reservoirs to ongoing viremia during
therapy and viral rebound after cessation of therapy [50,51,52]. A
heterogeneous latent reservoir could complicate development of
effective eradication strategies aimed at purging the latent
reservoir. One of the latently infected cell types identified,
transitional memory CD4 T-cells, are latently infected in vivo
and may be maintained by homeostatic proliferation despite
prolonged antitretroviral therapy [23]. If these latently infected
cells could be specifically targeted in vivo it is possible that other
latent reservoirs might naturally decay over time [22]. Our results
demonstrate that these transitional memory CD4 T cells may be
easily targeted by T-cell activators, including prostratin. Although
additional studies focusing on dissecting the different reactivation
properties of these discrete latently infected cell populations are
urgently needed, the model system presented here provides the
flexibility to begin identifying optimal reactivation strategies.
One strategy to purge the latent reservoir involves cytokines or
small molecules to attack different molecular pathways that
maintain latency. Several studies suggested that combinations of
NF-kB inducers (e.g., prostratin or PMA) and HDAC inhibitors
(valproic acid or trichostatin A) might act synergistically
[44,45,46]. We observed modest synergy with some combinations
of activators. However, in agreement with previous reports, this
synergy was often transient and lacked consistency between
different donors [45,46]. Our results in this primary CD4 T-cell
model suggest that prostratin alone may be nearly as potent as this
Figure 5. Analyses of reactivation profiles in latently infected transitional memory and central memory CD4 T cells. (A)
CD4+CD45RO+ cells were purified by single step negative selection and HIV latency was established in these cells as described above. Cells were
plated in 96-well plates and stimulated with 200 nM PMA with 1.5 mM ionomycin, anti-CD3+anti-CD28 beads (ratio 1:1), 62.5 ng/ml IL-7, 10 mM
prostratin, or left unstimulated for 24 h. Cells were stained with CD45RA-APC-H7, CCR7-PE-Cy7, CD27-APC, and CD45RO-FITC (NL4-3 mCherry:Luc) or
CD45RO-PE (NL4-3 GFP), and analyzed for receptor expression and viral reporter expression. To obtain fold stimulation ratios, data were normalized
as the percentage of cells expressing the viral reporter with the indicated stimulation divided by the % cells expressing the viral reporter in the
absence of stimulation. Data shown represent an average of results obtained from four independent donors for each viral construct. Error bars
represent +/2 SEM. (B) CD4+CD45RO+ cells (upper panel) were sorted for CCR7+CD27+ central memory cells (TCM) and CCR7-CD27+ transitional
memory cells (TTM). Cells were cultured for 2 days and then infected by spinoculation of NL4-3 mCherry:Luc. At the time of infection, cells were
analyzed by flow cytometry for receptor expression to determine the relative levels of CCR7 expression in each sorted population (lower panel). (C)
Latently infected cells were either left unstimulated or stimulated for 30 h with the indicated inducers. Two independent donors are shown, and fold
change was determined as described above for luciferase levels.
doi:10.1371/journal.pone.0030176.g005
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differences in the synergistic activation observed with combina-
tions of prostratin and SAHA, if confirmed in patients, would
dampen enthusiasm for this approach. The chromatin environ-
ment might have a more significant role in establishing latency in
proliferating cell lines than in quiescent primary CD4 T cells.
Additionally, the activation and binding of strong transcription
factors to the HIV LTR could interrupt RNA Pol II transcrip-
tional interference from upstream promoters, a process that is
known to help maintain HIV latency [53,54,55]. Our findings
certainly raise the possibility that non-toxic single agents might
prove capable of mounting a strong attack on the latent reservoir.
One very important unanswered question in the field is which of
the primary CD4 T-cell models most closely recapitulates the
biology of HIV latency occurring in vivo. While our model has
several attractive features including the ability to rapidly establish
latency in specific memory CD4 T-cell subsets and to test the
effects of inducers on these cellular reservoirs, it will be important
to test this model side-by-side with others. Only by carefully
comparing results from the different models to results obtained
with cells isolated from HIV-infected patients on HAART will it
be possible to identify the best in vitro models for in vivo HIV
latency.
As new translational approaches for eliminating the latent
reservoir emerge, a flexible, high-throughput, and highly repro-
ducible model of latent HIV-1 infection becomes increasingly
important. The versatility of this primary cell model could make it
useful for studies ranging from high-throughput compound
screening to molecular characterization of the mechanisms of
HIV-1 latency to studies of reservoirs within different memory
CD4 T-cell subsets. We hope that this model will help overcome a
major barrier in the HIV latency field allowing the rapid
acquisition of data previously considered unobtainable.
Supporting Information
Figure S1 (a) Uninfected peripheral blood cells were
purified by one-step negative selection for either total
CD4 T cells or CD45RO+ CD4 memory T cells. 24 hours
after isolation uninfected cells were either stained with CD4-FITC
and CD3-APC or CD45RO-FITC and CD45RA-APC and
analyzed by flow cytometry. (b) Reactivation profiles of cells
latently infected with NL4-3 luciferase. Latently infected
cells were cultured with media alone or media containing 200 nM
PMA and 1.5 mM ionomycin and harvested after 48 hours of
culture. Luciferase levels are reported as relative light units (RLU)
and have been normalized to total protein content in cell lysates to
control for different cellular proliferation rates. (c) Uninfected
peripheral blood cells were purified by one-step nega-
tive selection for either total CD4 T cells or resting
(CD25-/CD69-/HLA-DR-) CD4 T cells. Cells were infected
and cultured as described in (b).
(TIF)
Figure S2 Reactivation profiles of cells latently infected
with NL4-3 luciferase. Latently infected cells generated from
10 representative uninfected donors were cultured with media
alone or media containing 200 nM PMA and 1.5 mM ionomycin
and harvested after 48 hours of culture. Luciferase levels are
reported as relative light units (RLU) and have been normalized to
total protein content in cell lysates to control for different cellular
proliferation rates.
(TIF)
Figure S3 CD4 T cells were activated for 3 days prior to
infection. Activated cells were infected by spinoculation with
NL4-3 GFP virus as described above. Immediately after
spinoculation, cells were washed three times and cultured for
48 hours in the absence of drug or in the presence of the indicated
concentration of raltegravir or 118-D-24. Cells were evaluated for
GFP expression 48 post-infection. 100% infection was scored as
the percentage of GFP+ cells obtained in the absence of drug.
(TIF)
Figure S4 Uninfected CD4 T cells were treated for
48 hours with PHA alone (10 and 5 mg/ml), IL-2 alone
(500, 100 and 10 U/ml) or PHA and IL-2 in combination
at indicated concentrations. Cells were analyzed by flow
cytometry to determine the percentage of cells expressing CD25 or
CD69 (a) and cell viability (b). Based on activation marker
expression and viability, optimal concentrations were determined
to be 10 mg/ml for PHA alone, 100 U/ml for IL-2 alone, 10 mg/
ml/100 U/ml for PHA+IL-2.
(TIF)
Figure S5 Latently infected cells were generated as
described in Figure 1 with NL4-3 GFP virus. Cells were
either cultured in the presence of media alone or stimulated with
200 nM PMA, 200 nM PMA with 1.5 mM ionomycin, 10 mg/ml
PHA, 10 mg/ml PHA with 100 units/ml IL-2, 10 ng/ml TNF-a,
anti-CD3+anti-CD28 beads (ratio 1:1), 100 units/ml IL-2,
62.5 ng/ml IL-7, or 12.5 ng/ml IL-15. Cells were harvested after
48 hours of stimulation and GFP was analyzed by flow cytometry.
All stimulations were performed in triplicate with error bars
representing +/2 SD. Results are representative of experiments
performed in 3 different donors.
(TIF)
Figure S6 Cells infected with NL4-3 GFP were treated
for 24 hours with the indicated concentration of com-
pounds. Viability (right panels) and reactivation profiles (left
panels) are representative of independent experiments performed
with at least 3 independent donors.
(TIF)
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